A new AHI-1-BCR-ABL-JAK2 interaction complex has recently been identified and this complex regulates transforming activities and drug resistance in CML stem/progenitor cells. Here, JAK2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.